Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
6hon MSN
Combination treatment benefits patients with advanced breast cancer that has spread to the brain
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The ...
Icotrokinra is a once-daily, empty-stomach oral peptide that antagonizes IL‑23R, aiming to match biologic pathway selectivity ...
TOS-358 is an oral, highly selective, pan-mutant, covalent PI3Ka inhibitor that achieves >95% continuous target engagement ...
6hon MSNOpinion
RFK Jr. just put Florida in the Alzheimer's fight | Opinion
HHS Secretary Robert F. Kennedy Jr. appointed Michelle Branham as chair of the federal Advisory Council on Alzheimer’s ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...
Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology ...
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance ...
Explore 6 Maryland biotech companies with recent funding, ready to bring their breakthrough technologies to the clinic.
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR?)-targeting ant ...
Richardson, MD, gave an overview of the ways that CELMoDs are poised to impact the landscape of multiple myeloma treatment at ...
Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biologyVANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results